It's a wrap: GSK and Novartis megadeal completes

GlaxoSmithKline and Novartis have completed the landmark three-part transaction that they announced last April. GSK, which is affected more significantly than its larger European peer by the resulting changes, says it will hold an investor meeting on 6 May where it will provide 2015 earnings guidance and profile the medium and long-term shape of the company.

GSK hopes the $20bn transaction will give it a much-needed shot in the arm. When presenting the company's 2014 annual...